Empowering dendritic cell cancer vaccination: the role of combinatorial strategies
- PMID: 30360963
- DOI: 10.1016/j.jcyt.2018.09.007
Empowering dendritic cell cancer vaccination: the role of combinatorial strategies
Abstract
Dendritic cells (DCs) are bone marrow-derived immune cells that play a crucial role in inducing the adaptive immunity and supporting the innate immune response independently from T cells. In the last decade, DCs have become a hopeful instrument for cancer vaccines that aims at re-educating the immune system, leading to a potent anti-cancer immune response able to overcome the immunosuppressive tumor microenvironment (TME). Although several studies have indicated that DC-based vaccines are feasible and safe, the clinical advantages of DC vaccination as monotherapy for most of the neoplasms remain a distant target. Recently, many reports and clinical trials have widely used innovative combinatorial therapeutic strategies to normalize the immune function in the TME and synergistically enhance DC function. This review will describe the most relevant and updated evidence of the anti-cancer combinatorial approaches to boost the clinical potency of DC-based vaccines.
Keywords: cancer vaccines; combination strategies; dendritic cell vaccines; dendritic cells; immunotherapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Immunotherapy. 2016 Oct;8(10):1205-18. doi: 10.2217/imt-2016-0071. Immunotherapy. 2016. PMID: 27605069 Free PMC article. Review.
-
The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?Cancer Immunol Immunother. 2021 Jul;70(7):1797-1809. doi: 10.1007/s00262-020-02805-3. Epub 2021 Jan 1. Cancer Immunol Immunother. 2021. PMID: 33386466 Free PMC article. Review.
-
Dendritic Cells and Cancer Immunity.Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 Oct 25. Trends Immunol. 2016. PMID: 27793569 Free PMC article. Review.
-
Dendritic cell-based immunotherapy: a basic review and recent advances.Immunol Res. 2017 Aug;65(4):798-810. doi: 10.1007/s12026-017-8931-1. Immunol Res. 2017. PMID: 28660480 Review.
-
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy.Pharmacol Res. 2020 Sep;159:104980. doi: 10.1016/j.phrs.2020.104980. Epub 2020 Jun 3. Pharmacol Res. 2020. PMID: 32504832 Review.
Cited by
-
Telomerase-Targeted Cancer Immunotherapy.Int J Mol Sci. 2019 Apr 12;20(8):1823. doi: 10.3390/ijms20081823. Int J Mol Sci. 2019. PMID: 31013796 Free PMC article. Review.
-
MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells.Ann Transl Med. 2020 Nov;8(22):1494. doi: 10.21037/atm-20-6388. Ann Transl Med. 2020. PMID: 33313239 Free PMC article.
-
The Telomere Length Signature in Leukemias-From Molecular Mechanisms Underlying Telomere Shortening to Immunotherapeutic Options Against Telomerase.Cancers (Basel). 2025 Jun 10;17(12):1936. doi: 10.3390/cancers17121936. Cancers (Basel). 2025. PMID: 40563586 Free PMC article. Review.
-
Telomeres and telomerase in oncogenesis.Oncol Lett. 2020 Aug;20(2):1015-1027. doi: 10.3892/ol.2020.11659. Epub 2020 May 21. Oncol Lett. 2020. PMID: 32724340 Free PMC article. Review.
-
Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA.Pharmaceutics. 2020 Mar 1;12(3):210. doi: 10.3390/pharmaceutics12030210. Pharmaceutics. 2020. PMID: 32121531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources